Garenoxacin FDA Approval Status
FDA Approved: No
Generic name: Garenoxacin
Company: Schering-Plough Corporation
Treatment for: Bacterial Infection
Garenoxacin is an investigational broad-spectrum quinolone antibiotic for the treatment of gram-positive and gram-negative bacterial infections.
In August 2006, Schering-Plough Corporation announced the withdrawal of the New Drug Application (NDA) for garenoxacin.
Development timeline for Garenoxacin
| Date | Article |
|---|---|
| Feb 13, 2006 | Schering-Plough Reports Garenoxacin NDA Accepted for FDA Review |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
